NUVISAN Innovation Campus Berlin (ICB) is a dynamic contract research institute, founded by the acquisition of a complete pharma R&D unit from Bayer. Based on decades of experience and covering a broad range of disease indications, NUVISAN ICB provides fully integrated drug discovery and early development services to pharma/biotech and startup/VC clients.
NUVISAN Pharma Services Group is a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO) offering integrated and coupled solutions along the drug development value chain from target identification to the patient, with all supporting services (DMPK, GMP synthesis, formulation development and analysis, bioanalysis, Phase 1 CPU, clinical trial supplies and monitoring).
